Han Sohn, MD
Otolaryngology · Baltimore, MDNPI 1811916570
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $808 of the $1,224 with a category attached, or 66.0%. Neurent Medical Limited accounts for 66.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $828 and has fallen 87.0% since, to $108 in 2025.
Across 12 payments — averaging $102.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurent Medical Limited$808
- Sanofi-aventis U.S. LLC$216
- Optinose US, Inc.$90
- Ambu Inc.$59
- Smith+Nephew$21
- GSK$17
- plus $14 from 1 others
What the payments were for
- Consulting fees$80866%
- Food & beverage$36029%
- Education$575%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurent Medical Limited | 2 | $808 |
| Sanofi-aventis U.S. LLC | 2 | $216 |
| Optinose US, Inc. | 4 | $90 |
| Ambu Inc. | 1 | $59 |
| Smith+Nephew | 1 | $21 |
| GSK | 1 | $17 |
| Acclarent, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,224 in reported general payments places this provider in the 55th percentile of 222 otolaryngology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 104 | $1,756 |
| Ipratropium Bromide | 41 | $1,377 |
| Azelastine Hcl | 14 | $1,031 |
| Omeprazole | 73 | $1,028 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 84 | $954 |
| Ofloxacin | 39 | $879 |
| Mometasone Furoate | 54 | $852 |
| Cefdinir | 21 | $506 |
| Montelukast Sodium | 18 | $492 |
| Doxycycline Hyclate | 58 | $442 |
| CefuroximeCefuroxime Axetil | 12 | $324 |
| Levocetirizine Dihydrochloride | 14 | $318 |
| Clindamycin Hcl | 22 | $181 |
| Methylprednisolone | 27 | $166 |
| Pantoprazole Sodium | 11 | $148 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Baltimore
- Marc DubinBaltimore$350K
- Patrick HaBaltimore$41K
- Andrew LaneBaltimore$34K
- Jean KimBaltimore$29K
- Nicholas RowanBaltimore$25K
- Rodney TaylorBaltimore$18K
- Kyle HattenBaltimore$12K
- Alexander HillelBaltimore$11K
- Carole FakhryBaltimore$11K
- Lee AkstBaltimore$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.